Program
THDBH120
A development code. Also written as “THDBH120 injection”, “THDBH120 injection (SAD)” and “THDBH120 injection (MAD)”.
Its studies are mostly in Overweight · Diabetes Mellitus, Type 2 · Obesity, led by Tonghua Dongbao Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tonghua Dongbao Pharmaceutical | 41 open or running | phase 2since Jun 16, 2025 | Dec 17, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 17, 2024First study: phase 1 study in HealthyFirst studyNCT06744868 · 72 enrolled · China
- Apr 23, 2025Phase 1 study in ObesityNCT06951945 · 36 enrolled · China
- Jun 5, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07020949 · 49 enrolled · China
- Jun 16, 2025Phase 2 study in OverweightNCT07036601 · 276 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07036601Overweight · China | 2 | Recruiting | Feb 13, 2026 | 276 |
| NCT07020949Diabetes Mellitus, Type 2 · China | 1 | Completed | Nov 27, 2024 | 49 |
| NCT06951945Obesity · China | 1 | Completed | Dec 23, 2024 | 36 |
| NCT06744868Healthy · China | 1 | Completed | Sep 22, 2024 | 72 |
How it is read
Names in the registry
- “THDBH120 injection”, 3 entries
- “THDBH120 injection (SAD)”, 1 entry
- “THDBH120 injection (MAD)”, 1 entry
Codes read as this program: THDBH120.
Conditions, from the studies’ own filings
- Overweight, 1 study
- Diabetes Mellitus, Type 2, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.